eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2019
vol. 23
 
Share:
Share:
more
 
 
Review paper

The potential influence of breast cancer estrogen receptors’ distribution on active DNA demethylation

Kinga Linowiecka, Olga Urbanowska-Domańska, Jolanta Guz, Marek Foksiński

Contemp Oncol (Pozn) 2019; 23 (2): 74-80
Online publish date: 2019/05/27
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

Alterations in DNA methylation pattern are proven to have an impact on cancerogenesis. Novel developments in this field have heightened the need to establish the involvement of drugs used in cancer treatment in the epigenome. In the light of recent discoveries, epigenetic processes, including DNA methylation, may affect regulation of crucial genes implicated in drug response and drug targets [1]. Current experimental evidence has demonstrated that an active DNA demethylation process can affect DNA methylation pattern [2]. Tamoxifen, as a leading drug, which belongs to selective estrogen receptor modulators (SERMs), has been in clinical use for treatment and prevention of hormone-dependent breast cancer for nearly 40 years. Since its discovery, the use of tamoxifen has evolved by embracing its ability to act like estrogen in association with G-protein coupled receptors or antiestrogen in association to estrogen nuclear receptors [3, 4]. Given tamoxifen’s facility to act like an agonist or antagonist of estrogen receptors [5], its pharmacological activity may be more complex than just control estrogen activity. Thus, the role of this agent may be potentially involved with other factors or processes which occur in cells.
Active demethylation processes are essential during embryonic development and cell differentiation, although they can be modulated by environmental changes (e.g. after chemotherapy), which may manifest as random mutations [6]. Epigenetic modifications in the human genome may affect gene expression, particularly tumor suppressor genes, genes involved in apoptosis regulation and oncogenes [7], as well estrogen-dependent genes [8]. The level of epigenetic marks is flexible and mostly is associated with the response to hypomethylating factors.

DNA methylation and demethylation

The level of gene expression in cells is often conditioned by various epigenetic modifications. The most fundamental and widely described epigenetic alteration is DNA methylation of the cytosine residue, which in turn leads to formation of 5-methylcytosine (5-mC), the fifth DNA base [9]. Such terminology reflects the relative abundance of 5-mC content in the human genome: approximately 4% of cytosine residues are methylated [10]. DNA methylation is a physiological phenomenon, which takes part in cellular development and differentiation; however, it also plays a crucial role in the ageing process and carcinogenesis [11]. Vertebrate genomes are generally methylated in CpG islands, which are located at promoter regions of genes. The presence of multiple methylated CpG islands of promoters causes gene silencing [12]. Apart from DNA methylation, the 5-mC level is dependent on active DNA demethylation, which is being currently explored. Active DNA demethylation involves TET, and possibly AID proteins [13]. TET (ten-eleven-translocation) proteins are 2-oxoglutarate dependent dioxygenases (2-OGDDs), and the process catalyzed by these enzymes requires 2-oxoglutarate as a co-substrate, and Fe2+ and ascorbate as co-factors. Their catalytic function involves oxidation of 5-mC to 5-hydroxymethylcytosine (5-hmC), and then to 5-formylcytosine (5-fC), and 5-carboxylcytosine (5-caC). AID protein is an activation-induced deaminase which is implicated in deamination of 5-mC to thymine, and possibly 5-hmC to 5-hydroxymethyluracil (5-hmU) [14]. Additionally, TET enzymes could generate 5-hmU from thymine [15]. Cytosine modifications can be subsequently excised by TDG (thymine DNA glycosylase) or SMUG (single-strand selective monofunctional uracil-DNA glycosylase1) in the base excision repair system (BER) [16] (Fig. 1). DNA glycosylases replace modified bases with cytosines, which terminates in demethylated DNA formation [17]. The main role of TET proteins is preserving the fidelity of DNA methylation/demethylation at different stages of cellular development and differentiation. Recent research in this field has revealed that the differences in TET expression are already visible in oocytes and zygotes: from the highest expression of TET3 to intermediate of TET2, and hardly observed for TET1. Moreover, TET expression changes dramatically during further cell development: at the 4-cell stage TET1 and TET2 are expressed at a higher level than TET3, and this tendency remains at the same level until blastocyst formation [18].
Epigenetic modifications cause disturbances in regulation of gene expression, including drug metabolism and distribution [1]. A considerable amount of literature has been published on the connection of 5-hmC with cancer development. It was found that many cancers reveal DNA hypomethylation [20–22]. A large and growing body of literature data has demonstrated that changes of 5-mC level imply 5-hmC depletion in many types of cancers [23, 24]. Literature data suggest that 5-hmC may be involved in gene regulation [25]. Moreover, an impaired DNA methylation pattern is linked with activation or repression of key genes, which in turn may lead to expression changes and cancer progression [7].
5-hmC level is regarded as a biomarker of malignant transformation, which is considered in evaluating the active DNA demethylation process. The potential role of active DNA demethylation derivatives as a novel predictive factor linked with hormonal therapy outcome has not been investigated yet. Recent research has revealed that 5-hmC is decreased in cancer cells, including breast cancer cells [23, 26]. Literature data suggest that 5-hmC level is positively associated with 5-mC level in breast cancer patients. Moreover, it was demonstrated that decreased levels of 5-mC and 5-hmC are potentially correlated with poor disease-free survival (DFS) and disease-specific survival (DSS) in breast cancer patients with ER/PR(-) in comparison to those with ER/PR(+) [27]. Although literature data indicate that 5-hmC is reduced in many types of cancer, there is a gap in terms of its possible predictive role in therapy outcome.
Recent developments have focused on the role of TETs and TDG in breast cancer patients. Yang et al. investigated the relationship between TET1 mRNA level and overall survival among breast cancer patients treated with anthracyclines. Additionally, they suggested that high TET3 and TDG expression might be a significant predictive factor of clinical outcome in this group [28]. However, it still remains unclear why TET and TDG expression is unsettled in different types of tumors. Since 5-hmC and its modifications are products of TET proteins’ activity, it is suggested that alterations in gene expression are associated with 5-mC derivatives content. Since the overwhelming majority of alterations in TET activity are not related to genetic mutations, it suggests that other factors are potentially responsible for such changes.

Breast cancer subtypes

Breast cancer is the most frequent malignancy amongst women worldwide. It affects over 2.1 million women per year globally and it is the cause of death for almost 600 thousand of them [29]. This type of cancer, similarly to others, displays global hypomethylation as a result of genome instability. Furthermore, it was conclusively demonstrated that alterations in DNA methylation of pivotal genes (BRCA, p53, ER) are involved in cancer progression [30]. Changes in DNA methylation are associated with molecular subtypes of breast cancer, which may suggest an important role of impaired DNA methylation in carcinogenesis [31].
Breast cancer is classified into five biological subtypes based on expression of ER, PR, human epidermal growth factor 2 (HER2) receptors, and nuclear antigen Ki-67 (Table 1). According to the 5th St Gallen International Breast Cancer Conference, expression of steroid hormones and HER2 receptors constitutes a crucial prognostic and predictive factor of breast cancer outcome [33]. The vast majority of breast cancer cases (approximately 60–70%) are ER(+) and PR(+) positive. Breast cancers with high expression of steroid hormone receptors are less invasive, and have better prognosis overall. The triple negative subtype has the worst prognosis, and it accounts for approximately 15–25% of breast cancer cases. Regardless of potential clinical recovery, receptor expression determines the treatment strategy: trastuzumab for HER2 (+) subtypes or drugs affecting estrogen synthesis or estrogen receptors for those with ER/PR expression [32].

Breast cancer receptors’ significance

ERs are members of the nuclear receptor superfamily of ligand-activated transcription factors. After ligand activation, ERs undergo conformational changes, and as a result they could bind to estrogen response elements (ERE) in DNA and have an impact on regulation of gene expression [34]. Isoforms of ER (ER and ER) are under the control of two genes, ESR1 and ESR2. Contrary to ER, isoforms of progesterone receptor (PRA and PRB) are coded by one gene, PGR [35]. The expression and activity of PR are regulated by ER: PR is expressed as a result of ER activation [36].
The elevated estrogen activity in cancer cells is connected with increase of ER quantity; thus ER is used as a target of hormonal therapy of breast cancer. Moreover, the grade of malignancy and stage of differentiation are associated with ER expression. In contrast to ER, ER is expressed mainly in healthy mammary gland [37]. Moreover, ER could exert an antagonistic effect on ER action in certain tissues, which in turn may lead to decrease of cellular proliferation. Reduced ER expression in cancer suggests that this isoform has suppressor activity in hormone-dependent tissue, e.g. in mammary gland [38].
In 2000 Filardo et al. observed that the rapid response to 17-estradiol is a consequence of extracellular regulated kinase (ERK) activation, which was not connected with ER or ER, but with a G-protein-coupled receptor named GPR30/GPER [39]. Later, it was conclusively demonstrated that GPER also binds estradiol with high affinity and is connected with rapid non-genomic signaling of estradiol [40]. GPERs are classified as membrane receptors, although they may also occur in cytoplasm and nucleus [41].
The HER family is arranged in regulation of growth and development in breast cancer cells. HERs, in contrast to ER and PR, are epidermal growth factor receptors (EGFR) expressed in the cell membrane. Due to the fact that HER2 acts without a known ligand, it constitutively occurs in active conformation, and undertakes dimer formation with another EGFR. Hetero- or homodimerization leads to tyrosine kinase phosphorylation, and activation of the signaling pathway [42]. HER2 (+) occurs only in 15% of breast cancer patients; however, 10% of them also expressed ER(+) [43].
It is becoming increasingly clear that there is a high probability that abnormal cell growth found in breast carcinoma might be the result of impaired up-regulation of ER, GPER and HER2. The potential signaling pathways are able to stimulate each other: G protein-coupled estrogen receptor can trigger HER2 signaling, while tyrosine kinases cascade preceded by HER2 activation may phosphorylate and initiate the activation of ER and its proteins [44, 45]. Receptors’ expression in breast cancer determines the clinical outcome. Hence, it could be possible that the DNA methylation pattern varies between human breast cancer cells with diversified expression of receptors.
Estrogens as natural ER ligands are implicated in growth and proliferation of cells, e.g. in mammary gland. Nevertheless, excessive estrogen exposure may have an impact on promotion and progression of breast cancer in humans [46]. Inhibited proliferation of cancer cells after high concentrations of -estradiol (E2) was also observed in human cancer cell lines [47]. Moreover, E2 may act as a gene expression regulator though its ability to bind ER. Based on literature data, it was suggested that E2 can affect DNA methylation by promoting demethylation of CpG islands in promoter regions of genes [48, 49]. Furthermore, a recent study revealed that E2 supplementation of cultured cells resulted in almost entire removal of 5-mC in the SVEP1 gene promoter, and thus increased the unmethylated DNA level [50].

Biochemistry of tamoxifen

There are three possible treatment strategies of hormone-dependent breast cancer: arresting of estrogen synthesis via aromatase inhibitors, competitive binding to estrogen receptors and modulating their activity by antiestrogens, and prevention of ER signaling by causing degradation of ER by selective estrogen degraders (SERDs) [51]. The second group, represented widely as selective estrogen receptor modulators (SERMs), has been in clinical use for nearly 40 years [52].The best known representative of SERMs is tamoxifen, which is currently used in all stages of ER(+) breast cancer in pre- and postmenopausal women, and in ductal carcinoma in situ [53]. Moreover, tamoxifen is used for prevention of breast cancer for women at very high risk of developing the disease [54]. Additionally, longer tamoxifen treatment, up to 10 years, results in a 50% decrease in breast cancer mortality in the course of the second decade after diagnosis [55]. Based on pharmacological research, tamoxifen is transformed into three active metabolites in the human organism: 4-hydroxytamoxifen, N-desmethyltamoxifen, and 4-hydroxy-N-desmethyltamoxifen (endoxifen) [56]. Conversion of tamoxifen implicates hepatic CYP2D6 and CYP3A4/3A5 cytochromes, which metabolize tamoxifen to its metabolites in two different manners: to N-desmethyltamoxifen (CYP3A4/3A5), and further to 4-hydroxy-N-desmethyltamoxifen (CYP2D6), or to 4-hydroxytamoxifen (CYP2D6) and then to 4-hydroxy-N-desmethyltamoxifen (CYP3A4/3A5) [57]. It has been established by pharmacological profiling that tamoxifen is a prodrug, hence its therapeutic action results from its active metabolites: 4-hydroxytamoxifen and endoxifen [58]. The affinity of 4-hydroxytamoxifen and endoxifen to ER and ER is considerably similar, much the same as the other antiestrogens associated with regulation of estrogen-dependent gene expression [59]. However, given that the plasma level of endoxifen is 5–10 fold higher compared to 4-hydroxytamoxifen, it is suggested that this metabolite is presumably a key tamoxifen derivative accountable for pharmacological activity of tamoxifen in the human organism [60].

Mechanisms of SERM action in breast cancer cells

SERMs may act as antagonists or agonists of ERs depending on type of receptor: nuclear or G protein-coupled. The antagonistic action of SERMs is associated with nuclear ERs and connected to breast cancer treatment. After binding to ER, tamoxifen evokes the receptor’s conformational changes, but distinct from the ER-estrogen complex. The tamoxifen-ER bond dimerizes and translocates to the nucleus, where it prevents transcription of estrogen-dependent genes by attaching to estrogen response elements (ERE) in DNA [61]. This successively results in inhibition of estrogen activity, which is connected with growth and proliferation of cells [62, 63]. As estrogen receptor agonists, SERMs affect GPERs, which has been identified as a main factor in rapid responses to estrogens [64]. Tamoxifen activation of GPER results in modification of the estrogen receptor or its co-activators by phosphorylation, which can cause independent ligand activation or an impaired response to other ER regulators [27] (Fig. 2). This type of interaction occurs mainly in bones and liver [3]. However, it is possible that estrogens and SERMs affect impaired cell growth and proliferation though activation of GPERs, and it may be the predominant pathway in transformation of breast cancer cells into cells resistant to hormone therapy. Hence, it could conceivably be suggested that the role of tamoxifen is not only limited to involvement in regulation of estrogen-induced genes.
Tamoxifen as an antiestrogen may inhibit breast cancer cell growth and proliferation. However, acquired resistance to SERMs therapy still remains a problematical issue as adjuvant therapy is extended. The proposed mechanism of antiestrogen resistance is associated with GPER activation. It was suggested that GPERs may precede stimulatory estrogen signaling for proliferation and migration, regardless of ER expression [65]. Moreover, abnormal activity of ER caused by antiestrogens may be linked with changes in gene expression as a result of epigenetic modifications [8].
It was conclusively demonstrated that estrogen receptor signaling and DNA methylation are implicated in regulation of the cell cycle by modulating antiproliferative and proliferative genes [66, 67]. Although there are some data concerning partially overlapping gene regulation by estrogen signaling and DNA methylation, its detailed molecular mechanism and common target genes have remained enigmatic [8, 68]. It may be possible that SERMs can potentially interrupt estrogen receptor function and thus similarly affect the DNA methylation pattern. Moreover, several studies have proved that sustained SERM therapy can manifest distinct global gene expression and DNA methylation of promoters in breast cancer cells [69, 70].

Conclusions

The treatment of choice of ER/PR(+) breast cancer patients is based on the selective estrogen receptor modulator tamoxifen, which in long-term therapy serves as a considerably reliable drug. Of note, tamoxifen therapy leads to recovery in hundreds of thousands of ER/PR(+) breast cancer cases [71]. Since the discovery of tamoxifen, the use of the drug has evolved by embracing its ability to act like estrogen or antiestrogen depending on the receptor type and its localization around the body. Such ability created new possibilities in drug development and therapeutic use, i.e. tamoxifen acts like estrogen in osteoporosis treatment by preventing bone density loss, and like antiestrogen in breast cancer therapy by inhibition of estrogen action [72]. Hence, it is becoming increasingly clear that the action of SERMs at different target sites is more complex than just switching estrogen activity. It may be dependent on other factors and processes taking place in target cells.
Further studies are needed to determine whether tamoxifen, similarly to steroids, may evoke changes in the methylation pattern. Such research may provide new information, which may pave the way for new diagnostic and therapeutic methods as well as innovations in personalized medicine approaches.

Acknowledgments

The work was supported by the Polish National Science Center (2018/29/N/NZ3/02514).

The authors declare no conflict of interest.

References

1. Ivanov M, Barragan I, Ingelman-Sundeberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci 2014; 35: 384-396.
2. Baylin SB, Jones PA. A decade of exploring epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
3. Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007; 25: 5815-5824.
4. Lin BC, Suzawa M, Blind DR. Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Acivates SF-1 and Promotes Cell Proliferation. Cancer Res 2009; 69: 5415-5423.
5. Jordan VC, Lurie RH. Selective estrogen receptor modulation: A personal perspective. Cancer Res 2001; 61: 5683-5687.
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how to genome integrates intrinsic and environmental signals. Nature Genetics 2003; 33 Suppl: 245-254.
7. Han LL, Hou H, Zhou MJ, Ma ZL, Lin DL, Wu L, Ge YL. Abberant NDRG1 methyaltion assosciated with its decreased expression and clinicopathological significance in breast cancer. J Biomed Sci 2013; 20: 52.
8. Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64: 8184-8192.
9. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358.
10. Breiling A, Lyko F. Epigenetic regulatory functions of DNA modifications: 5-metylocytosine and beyond. Epigenetics Chromatin 2015; 8: 24.
11. Song L, Li Y. The role of stem cell DNA methylation in colorectal carcinogenesis. Stem Cell Rev 2016; 12: 573-583.
12. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
13. Jeschke J, Colignon E, Fuks F. Portraits of TET-mediated DNA hydromethylation in cancer. Curr Opin Genet Dev 2016; 36: 16-26.
14. Scourzic L, Enguerran M. Olivier AB. TET proteins and the control of cytosine demetylation in cancer. Genome Med 2015; 7: 9.
15. Olinski R, Starczak M, Gackowski D. Enigmatic 5-hydroxymethyluracil: Oxidatively modified base epigenetic mark or both? Mutat Res Rev 2016; 767: 59-66.
16. Hu L, Lu J, Cheng J, et al. Structural insight into substrate preference for TET-mediated oxidation. Nature 2015; 527: 118-122.
17. Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell 2011; 146: 866-872.
18. Wossidlo M, Nakamura T, Lepikhov K, et al. 5- Hydroxymethylocytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2011; 2: 241.
19. Zhang H, Zhu JK. Active DNA methylation in plants and animals. Cold Spring Harb Symp Quant Biol 2012; 77: 161-173.
20. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from human their normal counterparts. Nature 1983; 301: 89-92.
21. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. The 5-methylocytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883-9684.
22. Li J, Huang Q, Zeng F, Li W, He Z, Chen W, Zhu W, Zhang B. The prognostic value of global DNA hypomethylation in cancer: A meta-analysis. PLoS One 2014; 9: e106290.
23. Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylocytosine content is significantly reduced in tissue ste/progenitor cell compartments and in human cancers. Oncotarget 2011; 2: 627-637.
24. Kudo Y, Tateishi K, Yamamoto K, et al. Loss of 5-hydroxymethylocytosine is accompanied with malignant cellular transformation. Cancer Sci 2012; 103: 670-676.
25. Yildirim O, Li R, Hung JH, et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylocytosine marked genes in embryonic stem cells. Cell 2011; 147: 1498-1510.
26. Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids 2011; 870726.
27. Tsai KW, Li GC, Chen CH, et al. Reduction of global 5-hydroxymethylo-cytosine is poor prognostic factor in breast cancer patients, especially for ER/PR-negative subtype. Breast Cancer Res Treat 2015; 153: 219-234.
28. Yang L, Yu SJ, Hong Q, Yang Y, Shao ZM. Reduced Expression of TET1, TET2, TET3 and TDG mRNAa are associated with poor prognosis with early breast cancer. PLoS One 2015; 10: e0133896.
29. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
30. Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, Bignon YJ, Bernard-Gallon D. Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics 2014; 6: 651-664.
31. Holm K, Staaf J, Lauss M, et al. An integrated genomics analysis of epigenetic subtypes in human breast links DNA methylation patterns to chromatin states in normal mammary cells. Breast Cancer Res 2016; 18: 27.
32. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2013; 24: 2206-2223.
33. Goldhirsch A, Glick JH, Gelber RD. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2005; 16: 1569-1583.
34. Putnik M, Zhao C, Gustafsson JA, Wright KD. Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2012; 426: 26-32.
35. Yip C, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol 2014; 10: 2293-2301.
36. Kastner P, Krust A, Turcotte B, Tora L, Gronemeyer H, Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptors forms A and B. EMBO J 1990; 9: 1603-1614.
37. Chang J, Liu J, Li H, Li J, Mu Y, Feng B. Expression of ER beta gene in breast carcinoma and relevance in neoadjuvant therapy. Oncol Lett 2017; 13:1641-1646.
38. Treeck O, Lattrich C, Sprinwald A, Ortmann O. Estrogen receptors beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2010; 120: 557-565.
39. Filardo EJ, Quinn JA, Bland KI, Frackelton R Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G Protein- Coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660.
40. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-632.
41. Gururaj AE, Rayala SK, Vadlamundi RK, Kumar R. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 2006; 12: 1001s-1007s.
42. Zahnow CA. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 2009; 8: 1-21.
43. Dowsett M, Allred C, Knox J, at al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008; 26: 1059-1065.
44. Musgrove EA, Sutherland R. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
45. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003; 278: 2701-2712.
46. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids. 2015; 99 (Pt A): 8-10.
47. Zhao Z, Chen C, Liu Y, Wu C. 17beta-Estradiol treatment inhibits breast cancer proliferation, migration and invasion by decreasing MALAT-1 RNA level. Biochem Biophys Res Commun 2014; 445: 388-393.
48. Kubarek Ł, Jagodzinski PP. Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett 2007; 581: 1441-1448.
49. Wu Z, Sun X, Mei X, Zhang C, Pan W, Shi W. 17beta-oestradiol enhances global DNA hypomethylation in CD4-positive T cells from female patients with lupus, through overexpression of estrogen receptor-alpha-mediated down regulation of DNMT1. Clin Exp Dermatol 2014; 39: 525-532.
50. Glait-Santar C, Benayahu D. SVEP1 promoter regulation by methylation of CpG sites; et al. Gene 2011; 490: 6-14.
51. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen degraders (SERDs) in cancer treatment. Pharmacol Ther 2018; 186: 1-24.
52. Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxixcity and adverse effects of Tamoxifen and other ani-estrogen drugs. Pharmacol Ther 2013; 139: 392-404.
53. Hughes-Davies L, Caladas C, Wishart GC. Tamoxifen: the drug that came in from the cold. Br J Cancer 2009; 101: 875-878.
54. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
55. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816.
56. Jordan VC. New insights into metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007; 72: 829-842.
57. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature 2009; 9: 576-586.
58. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075.
59. Johnson MD, Zuo H, Lee KH, et. at. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-159.
60. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
61. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer 2002; 89: 817-825.
62. Chang XZ, Li DQ, Hou YF, et al. Identification of the fictional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
63. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naple Breast Cancer Group. Mechanisms of endorine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12: 721-747.
64. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010; 204: 105-114.
65. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiollini M, Picard D. Estrogenic GPR30 signaling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009; 28: 523-532.
66. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-4642.
67. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
68. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64: 3807-3813.
69. Fan M, Yan PS, Hartman-Frey C, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogen tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
70. Badia E, Duchesne MJ, Semlali A, Fuentes M, Giamarchi C, Richard-Foy H, Nicolas J-C, Pons M. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Cancer Res 2000; 60: 4130-4138.
71. Early Brest Cancer Triallists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on reccurence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
72. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001; 61: 5683-5687.

Address for correspondence

Olga Urbanowska-Domańska
Department of Oncology
Professor Franciszek Lukaszczyk Oncology Centre
2 dr Izabeli Romanowskiej St.
85-796 Bydgoszcz, Poland
e-mail: olga.urbanowska-domanska@o2.pl

Submitted: 8.04.2019
Accepted: 15.04.2019
Copyright: © 2019 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe